MedTrace Logo

A Study of a Live Intranasal Influenza Vaccine in Children With Cancer

NCT00906750 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2011-10-13

No results posted yet for this study

Summary

Eligible research subjects will be randomized to receive either FluMist or inactivated influenza vaccine then stratified by age and necessity to receive either one or two immunizations. Subjects requiring one immunization will be immunized at Day 0. Subjects requiring two immunizations will be immunized at Day 0 and Day 28. Subjects will be observed for 30 minutes following vaccination and given a diary card to record symptoms after each vaccination.

Conditions

Interventions

BIOLOGICAL

FluMist

FluMist is a live attenuated intranasal influenza vaccine

BIOLOGICAL

Inactivated influenza vaccine

Inactivated influenza vaccine

Sponsors & Collaborators

Principal Investigators

  • Silvana Carr, MD · St. Jude Children's Research Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906750 on ClinicalTrials.gov